Clinical trials: Hematologic Disease and Disorders
Hemophilia A
Safety,Efficacy and Pharmacokinetics Evaluation of SCT800 in Previously Treated Paediatric Patients With Severe Haemophilia A.
This study is a multicenter phase III uncontrolled open-label trial to evaluate the efficacy,safety and pharmacokinetics of SCT800 in regular prophylaxis and perioperative treatment in patients (<12 years old) with severe…
- Trial name
- NCT03947320
- Testing
- Recombinant Human Coagulation FVIII
- Volunteers
- 70 people
- Sponsor
- Sinocelltech Ltd.
Myeloid Malignancies, Acute Lymphocytic Leukemia
Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors
This Phase 1 study will evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD), and clinical activity of KT-253 in adult patients with relapsed or refractory (R/R) high grade myeloid malignancies, acute…
- Conditions
- Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphomas, Advanced Solid Tumors
- Trial name
- NCT05775406
- Testing
- KT-253
- Where
- 11 sites in United States
- Volunteers
- 52 people
- Sponsor
- Kymera Therapeutics, Inc.
Chronic Myeloid Leukemia
KRT-232 and TKI Study in Chronic Myeloid Leukemia
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Ph+ Chronic Myeloid Leukemia (CML) who have relapsed or are refractory or intolerant to a Tyrosine Kinase Inhibitor…
- Trial name
- NCT04835584
- Testing
- KRT-232, Dasatinib, Nilotinib
- Where
- 26 sites in United States, Canada and 6 more
- Volunteers
- 109 people
- Sponsor
- Kartos Therapeutics, Inc.
Acute Myeloid Leukemia
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Oral Venetoclax Tablets in Combination With Subcutaneously (SC) or Intravenously (IV) Injected Azacitidine in Colombia
Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow and is the most common acute leukemia in adults. This study will evaluate how well venetoclax in combination with azacitidine works to treat AML in adult…
- Trial name
- ESVECO (NCT05587049)
- Where
- 8 sites in Colombia
- Volunteers
- 70 people
- Sponsor
- AbbVie
Leukemia, Lymphoma
Clinical Trial of CAR-T in the Treatment of Relapsed and Refractory Hematopoietic and Lymphoid Tissue Tumors in Children
This is an open, single-arm, prospective，clinical study to evaluate efficacy and safety of Auto CAR-T cell injection in the treatment of recurrent or refractory Hematopoietic and Lymphoid Tissue Tumors in Children
- Trial name
- NCT04610125
- Testing
- Auto CAR-T, Cyclophosphamide,Fludarabine, Leukapheresis
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Chronic Immune Thrombocytopenia
A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia
The goal of the global Phase 1/2 clinical trial is to evaluate whether CID-103, a novel anti-CD38 monoclonal antibody, is safe and effective in adults with chronic immune thrombocytopenia (ITP).
- Trial name
- NCT07017725
- Testing
- CID-103
- Where
- 6 sites in China
- Volunteers
- 75 people
- Sponsor
- CASI pharmaceuticals, Inc.
Multiple Myeloma
Phase I Clinical Study of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple Myeloma
This is a single arm study to evaluate the efficacy and safety of BCMA-targeted CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.
- Trial name
- NCT06705725
- Testing
- CBG002 CAR-T Cell Suspension
- Volunteers
- 38 people
- Sponsor
- Carbiogene Therapeutics Co. Ltd.
Immune Thrombocytopenia
Hetrombopag for Pediatric Patients With Chronic Immune Thrombocytopenia
The purpose of this study is to investigate the efficacy, safety of Hetrombopag in children with previously treated chronic immune thrombocytopenia who are between 6 and 17 years of age. This is a 2 part study.
- Trial name
- NCT04737850
- Testing
- Hetrombopag
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Iron Deficiency Anemia
A Double-blind, Double-dummy, Parallel, Active-controlled, Randomized Trial to Evaluate Efficacy & Safety in Anemia Subjects
To evaluate the efficacy and safety of 12 weeks treatment with Ferrous (II) Glycine Sulphate Complex in comparison to Polyferose capsules in Chinese subjects with manifest Iron Deficiency Anemia.
- Trial name
- NCT01425463
- Testing
- Ferrous (II) Glycine Sulphate Complex, Polyferose
- Where
- 15 sites in China
- Volunteers
- 256 people
- Sponsor
- Sanol GmbH
Chemotherapy-induced Neutropenia
Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer
The purpose of the study is to compare safety and efficacy of a single dose of empegfilgrastimt a dose of 3 or 6 mg versus daily administration of filgrastim at a dose of 5 μg/kg/day.
- Trial name
- NCT01569087
- Testing
- empegfilrastim, filgrastim
- Where
- 5 sites in Russia
- Volunteers
- 60 people
- Sponsor
- Biocad
Multiple Myeloma
An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants
The purpose of this study is to describe contemporary, real-world patterns of participant characteristics, clinical disease presentation, therapeutic regimen chosen, and clinical outcomes in participants with newly diagnosed [ND]…
- Trial name
- NCT02761187
- Testing
- No Intervention
- Where
- 137 sites in United States, Belgium and 13 more
- Volunteers
- 4,253 people
- Sponsor
- Takeda
Chronic Myeloid Leukemia, Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Iclusig PMS in CML or Ph+ALL Patients
This is a Post-Marketing Surveillance (PMS) of Iclusig® Tablets in accordance with Korean regulations on Risk Management Plan (RMP).
- Trial name
- NCT03709017
- Testing
- Ponatinib
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Multiple Myeloma, Relapsed/Refractory Multiple Myeloma
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
This is a Phase 2, open-label, single-arm, multicenter study to assess the antimyeloma activity and further characterize the safety, tolerability, PK, and PD of cemsidomide in combination with dexamethasone in participants with…
- Trial name
- MOMENTUM (NCT07284758)
- Testing
- Cemsidomide, Dexamethasone
- Where
- 60 sites in United States, France and 4 more
- Volunteers
- 100 people
- Sponsor
- C4 Therapeutics, Inc.
Coagulopathy, Hemorrhage
Ascending Dose Study of FrontlineODP™ Spray Dried Plasma
This study in healthy volunteers is designed to assess the safety of infusing increasing doses of spray dried plasma (FrontlineODP).
- Trial name
- NCT05629338
- Testing
- Autologous Spray Dried Plasma
- Where
- 3 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Velico Medical
Multiple Myeloma
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab monotherapy, cevostamab plus pomalidomide and dexamethasone (Pd) or cevostamab…
- Trial name
- CAMMA 1 (NCT04910568)
- Testing
- Cevostamab, Tocilizumab, Pomalidomide
- Where
- 34 sites in United States, Australia and 11 more
- Volunteers
- 186 people
- Sponsor
- Genentech, Inc.
Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia
A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
The main purpose of this study is to confirm the correct dose of efgartigimod IV for treating patients aged 12 to younger than 18 years with chronic immune thrombocytopenia (ITP).
- Conditions
- Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia, ITP, Immune Thrombocytopenic Purpura
- Trial name
- Advance Jr (NCT07194850)
- Testing
- Efgartigimod IV
- Where
- 26 sites in France, Germany and 8 more
- Volunteers
- 24 people
- Sponsor
- argenx
Sickle Cell Disease
CS-206 in Patients With Sickle Cell Disease
The goal of this open label, single-arm clinical study is to learn about the safety and efficacy of CS-101 injection in treating sickle cell disease.
- Trial name
- NCT06565026
- Testing
- CS-206
- Where
- China
- Volunteers
- 5 people
- Sponsor
- CorrectSequence Therapeutics Co., Ltd
Eosinophilic Esophagitis
Safety and Pharmacokinetics of Orodispersible BT-11 in Active Eosinophilic Esophagitis
The proposed Phase 1b study design was a randomized, placebo-controlled, double-blind, study to evaluate the safety and pharmacokinetics of oral BT-11 in active eosinophilic esophagitis.
- Trial name
- NCT04835168
- Testing
- BT-11 low, BT-11 high
- Sponsor
- NImmune Biopharma
Leukemia, Lymphocytic, Chronic
Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)
Forodesine hydrochloride will be administered orally at a dose of 200 mg daily for 7 days each week for 4 weeks (cycle number 1). The drug will be administered once daily one hour prior to or two hours after meals.
- Trial name
- NCT00289549
- Testing
- forodesine hydrochloride (BCX-1777)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- BioCryst Pharmaceuticals
Gaucher Disease Type 1
A Clinical Study Evaluating LY-M001 Injection in the Treatment of Adult Patients With Type I Gaucher Disease
Gaucher disease (GD) is caused by mutations in the GBA1 gene, which leads to a lack or reduction of GCase activity. The consequences of this deficiency are generally attributed to the accumulation of the GCase substrate…
- Trial name
- GD (NCT06818838)
- Testing
- LY-M001
- Where
- 3 sites in China
- Volunteers
- 12 people
- Sponsor
- Lingyi Biotech Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.